Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.

Griffiths, Gareth, Fennell, D., Casbard, A., Nixon, L. and Lester, J. (2012) Vinorelbine in mesothelioma (VIM): a randomised phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma(MPM) expressing BRCA1- a study in progress.

Record type: Conference or Workshop Item (Poster)

Abstract

Mesothelioma is increasing worldwide. However there is no approved therapy in the second-line setting. Vinorelbine exhibits promising activity, however there has been no randomised evaluation or validation of biomarkers to support patient stratification. We have recently reported that BRCA-1 is an essential regulator of mesothelioma sensitivity to vinorelbine, and its expression is lost in approximately 38%1. The Cancer Research UK VIM trial is to be sponsored by the University of Leicester in collaboration with the Wales Cancer Clinical Trials Unit.

This record has no associated files available for download.